A Phase 2 interventional study of JointStem and Synvisc-One in Osteoarthritis, Knee, sponsored by Nature Cell Co. Ltd.. Completed at 2 sites in United States. Open to participants aged 22 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-08-10.
Sponsored by Nature Cell Co. Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 550th largest by enrollment of the 691 interventional ones that give a count, is one of 44 that started in 2016, is one of 111 in phase 2, and was the 286th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:
Lucas R. Cusumano, MD · Sites in United States
Ages 40+
VA Office of Research and Development · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 22 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
796 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 146 · Phase 3 89 · Phase 4 59
First in 1977; this study’s year is marked. 44 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 72 across the 691 interventional studies, 100 across the 101 observational. Of the 566 that completed or were terminated, 247 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
265 of 796 have an industry lead sponsor. The 10 most frequent:
Nature Cell Co. Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Nature Cell Co. Ltd. has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
54 of the studies in Osteoarthritis, Knee with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07151417Phase 3Walter Reed National Military Medical CenterUse of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | 2027-08-31 |
Add all 54 to your calendar (.ics) → With an account.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a double-blind, randomized, controlled study with two arms to evaluate JointStem as a treatment for subjects with osteoarthritis. Following a 2-week screening period, approximately 30 subjects will be randomly assigned into one of the following two arms in a 2:1 ratio (2 JointStem : 1 positive control). After each subject completes 6-month visit (Visit 6) and the data management team confirms all data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.Only subjects who are assigned will be requested to visit the study center for 9-month and 12-month follow-up visits (Visits 7 and 8). To see long-term effects of JointStem, all subjects who complete Visit 6 will be requested to visit the study center at 24-month after the injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
autologous adipose tissue derived mesenchymal stem cells (AdMSC)
Drug: JointStem
hyaluronic acid
Drug: Synvisc-One
Also known as: Active Comparator
Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group
Comparing the baseline and 6-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment
Time frame: Baseline and 6 months
Change From Baseline on Visual Analog Scale (VAS) in JointStem Group
Comparing the baseline and 6-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.
Time frame: Baseline and 6 months
MRI Improvement Evaluation in JointStem Group
Comparing the baseline and 6-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.
Time frame: 6 months
Change From Baseline on WOMAC Between JointStem and Positive Control Groups
Comparing the changes of WOMAC scores between JointStem and positive control groups at 6 months Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment
Time frame: Baseline and 6 months
Change From Baseline on VAS Between JointStem and Positive Control Groups
Comparing the changes of VAS scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.
Time frame: Baseline and 6 months
Change From Baseline on Knee Injury & Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups
Comparing the changes of KOOS values between JointStem and positive control groups at 6 months KOOS score = 100 - \[{(average score of each item) \* 100} / 4 \] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
Time frame: Baseline and 6 months
Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups
Comparing the changes of Lysholm Knee Scoring Scales between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
Time frame: Baseline and 6 months
Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups
Comparing the changes of IKDC scores between JointStem and positive control groups at 6 months IKDC score = {(sum of each item score) / 87} \* 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
Time frame: Baseline and 6 months
Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups
Comparing the changes of RAND-36 scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
Time frame: Baseline and 6 months
Change From Baseline on WOMAC in JointStem Group
Comparing the baseline and 9-month/12-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment
Time frame: Baseline, 9 months and 12 months
Change From Baseline on VAS in JointStem Group
Comparing the baseline and 9-month/12-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.
Time frame: Baseline, 9 months and 12 months
Comparison of MRI Improvement Evaluation in JointStem Group
Comparing the baseline and 9-month/12-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.
Time frame: Baseline, 6 months and 12 months
Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12
Comparing the baseline and 6-month/9-month/12-month Lysholm Knee Scoring Scale in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
Time frame: Baseline, 6 months, 9 months and 12 months
Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group
Comparing the baseline and 6-month/9-month/12-month KOOS scores in JointStem group KOOS score = 100 - \[{(average score of each item) \* 100} / 4 \] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
Time frame: baseline, 6 month, 9 month, 12 month
Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group
Comparing the baseline and 6-month/9-month/12-month IKDC scores in JointStem group IKDC score = {(sum of each item score) / 87} \* 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
Time frame: baseline, 6 month, 9 month, 12 month
Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group
Comparing the baseline and 6-month/9-month/12-month RAND-36 scores in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
Time frame: baseline, 6 month, 9 month, 12 month
| Milestone | JointStem | Synvisc-One |
|---|---|---|
| Started | 19 | 9 |
| Completed | 17 | 9 |
| Not completed | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
Comparing the baseline and 6-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group | -20.121 ± 21.0415 | — |
Comparing the baseline and 6-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change From Baseline on Visual Analog Scale (VAS) in JointStem Group | -32.5 ± 23.93 | — |
Comparing the baseline and 6-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.
| Participants | JointStem | Synvisc-One |
|---|---|---|
| Improvement | 5 | 0 |
| No Change | 5 | 0 |
| Progress | 8 | 0 |
Comparing the changes of WOMAC scores between JointStem and positive control groups at 6 months Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change From Baseline on WOMAC Between JointStem and Positive Control Groups | -20.505 ± 3.665 | -17.129 ± 5.3281 |
Comparing the changes of VAS scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change From Baseline on VAS Between JointStem and Positive Control Groups | -31.9 ± 4.90 | -30.6 ± 7.13 |
Comparing the changes of KOOS values between JointStem and positive control groups at 6 months KOOS score = 100 - \[{(average score of each item) \* 100} / 4 \] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Symptoms | 9.70 ± 2.888 | 14.83 ± 4.22 |
| Pain | 21.40 ± 3.975 | 19.04 ± 5.78 |
| ADL | 18.53 ± 3.937 | 15.94 ± 5.72 |
| Sport/Rec | 25.00 ± 5.123 | 26.68 ± 7.482 |
| QOL | 22.68 ± 5.383 | 11.15 ± 7.884 |
Comparing the changes of Lysholm Knee Scoring Scales between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups | 18.9 ± 3.97 | 19.9 ± 5.78 |
Comparing the changes of IKDC scores between JointStem and positive control groups at 6 months IKDC score = {(sum of each item score) / 87} \* 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups | 55.74 ± 2.223 | 54.24 ± 3.238 |
Comparing the changes of RAND-36 scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Physical Functioning | 17.2 ± 3.80 | 14.9 ± 5.52 |
| Role Limitation (Physical) | 20.7 ± 8.04 | 17.4 ± 11.73 |
| Role Limitation (Emotional) | 6.7 ± 6.615 | -6.74 ± 9.654 |
| Energy/Fatigue | 5.2 ± 3.91 | 4.5 ± 5.76 |
| Emotional well-being | -3.4 ± 2.31 | 0.5 ± 3.45 |
| Social Functioning | 14.71 ± 2.964 | 16.16 ± 4.312 |
| Pain | 21.59 ± 4.211 | 14.7 ± 6.18 |
| General Health | 2.91 ± 2.516 | 3.13 ± 3.668 |
Comparing the baseline and 9-month/12-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change from baseline at Month 9 | -21.216 ± 20.9653 | — |
| Change from baseline at Month 12 | -21.711 ± 19.7521 | — |
Comparing the baseline and 9-month/12-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change from baseline at Month 9 | -31.5 ± 25.52 | — |
| Change from baseline at Month 12 | -35 ± 24.56 | — |
Comparing the baseline and 9-month/12-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.
| Participants | JointStem | Synvisc-One |
|---|---|---|
| Month 6 Improved -> Month 12 Improved | 3 | — |
| Month 6 Improved -> Month 12 No Change | 1 | — |
| Month 6 Improved -> Month 12 Progress | 1 | — |
| Month 6 No Change -> Month 12 Improved | 1 | — |
| Month 6 No Change -> Month 12 No Change | 2 | — |
| Month 6 No Change -> Month 12 Progress | 2 | — |
| Month 6 Progress -> Month 12 Improved | 2 | — |
| Month 6 Progress -> Month 12 No Change | 0 | — |
| Month 6 Progress -> Month 12 Progress | 6 | — |
Comparing the baseline and 6-month/9-month/12-month Lysholm Knee Scoring Scale in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change from baseline at Month 6 | 18.3 ± 22.29 | — |
| Change from baseline at Month 9 | 16.1 ± 25.34 | — |
| Change from baseline at Month 12 | 17.1 ± 23.78 | — |
Comparing the baseline and 6-month/9-month/12-month KOOS scores in JointStem group KOOS score = 100 - \[{(average score of each item) \* 100} / 4 \] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change from baseline at Month 6 (Symptoms) | 9.02 ± 15.381 | — |
| Change from baseline at Month 9 (Symptoms) | 15.03 ± 13.677 | — |
| Change from baseline at Month 12 (Symptoms) | 15.41 ± 18.229 | — |
| Change from baseline at Month 6 (Pain) | 21.65 ± 20.386 | — |
| Change from baseline at Month 9 (Pain) | 23.98 ± 23.200 | — |
| Change from baseline at Month 12 (Pain) | 25.31 ± 21.219 | — |
| Change from baseline at Month 6 (ADL) | 18.66 ± 23.842 | — |
| Change from baseline at Month 9 (ADL) | 18.42 ± 25.017 | — |
| Change from baseline at Month 12 (ADL) | 21.90 ± 23.237 | — |
| Change from baseline at Month 6 (Sport/Rec) | 25.53 ± 23.915 | — |
| Change from baseline at Month 9 (Sport/Rec) | 28.42 ± 25.279 | — |
| Change from baseline at Month 12 (Sport/Rec) | 33.68 ± 24.486 | — |
| Change from baseline at Month 6 (QOL) | 23.36 ± 24.829 | — |
| Change from baseline at Month 9 (QOL) | 29.95 ± 27.228 | — |
| Change from baseline at Month 12 (QOL) | 28.96 ± 29.121 | — |
Comparing the baseline and 6-month/9-month/12-month IKDC scores in JointStem group IKDC score = {(sum of each item score) / 87} \* 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change from baseline at Month 6 | 7.03 ± 11.379 | — |
| Change from baseline at Month 9 | 10.95 ± 12.047 | — |
| Change from baseline at Month 12 | 9.63 ± 10.380 | — |
Comparing the baseline and 6-month/9-month/12-month RAND-36 scores in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment
| score on a scale | JointStem | Synvisc-One |
|---|---|---|
| Change from baseline at Month 6 (Physical Functioning) | 17.4 ± 22.13 | — |
| Change from baseline at Month 9 (Physical Functioning) | 18.7 ± 23.38 | — |
| Change from baseline at Month 12 (Physical Functioning) | 17.1 ± 28.69 | — |
| Change from baseline at Month 6 (Role Limitation_Physical) | 22.4 ± 36.22 | — |
| Change from baseline at Month 9 (Role Limitation_Physical) | 30.3 ± 38.71 | — |
| Change from baseline at Month 12 (Role Limitation_Physical) | 31.6 ± 40.69 | — |
| Change from baseline at Month 6 (Role Limitation_Emotional) | 8.77 ± 33.048 | — |
| Change from baseline at Month 9 (Role Limitation_Emotional) | 7.02 ± 30.604 | — |
| Change from baseline at Month 12 (Role Limitation_Emotional) | 8.77 ± 33.048 | — |
| Change from baseline at Month 6 (Energy/Fatigue) | 2.9 ± 20.70 | — |
| Change from baseline at Month 9 (Energy/Fatigue) | 5.3 ± 16.45 | — |
| Change from baseline at Month 12 (Energy/Fatigue) | 7.6 ± 18.81 | — |
| Change from baseline at Month 6 (Emotional well-being) | -3.4 ± 10.61 | — |
| Change from baseline at Month 9 (Emotional well-being) | -3.6 ± 11.31 | — |
| Change from baseline at Month 12 (Emotional well-being) | -4.0 ± 14.79 | — |
| Change from baseline at Month 6 (Social Functioning) | 13.82 ± 23.531 | — |
| Change from baseline at Month 9 (Social Functioning) | 14.47 ± 20.943 | — |
| Change from baseline at Month 12 (Social Functioning) | 7.24 ± 25.109 | — |
| Change from baseline at Month 6 (Pain) | 23.16 ± 21.982 | — |
| Change from baseline at Month 9 (Pain) | 23.95 ± 22.100 | — |
| Change from baseline at Month 12 (Pain) | 24.34 ± 21.967 | — |
| Change from baseline at Month 6 (General Health) | 3.51 ± 13.566 | — |
| Change from baseline at Month 9 (General Health) | 5.71 ± 10.502 | — |
| Change from baseline at Month 12 (General Health) | 2.85 ± 18.636 | — |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JointStem | 0/19 (0%) | 0/19 (0%) | 18/19 (94.7%) |
| Synvisc-One | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Event | JointStem | Synvisc-One |
|---|---|---|
| Injection site painGeneral disorders | 9/19 | 1/9 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/19 | 2/9 |
| Joint swellingMusculoskeletal and connective tissue disorders | 5/19 | 0/9 |
| Stiff kneesMusculoskeletal and connective tissue disorders | 4/19 | 1/9 |
| TendonitisMusculoskeletal and connective tissue disorders | 0/19 | 1/9 |
| BronchitisInfections and infestations | 2/19 | 1/9 |
| PneumoniaInfections and infestations | 0/19 | 1/9 |
| Ligament sprainInjury, poisoning and procedural complications | 2/19 | 1/9 |
| Ligament ruptureInjury, poisoning and procedural complications | 0/19 | 1/9 |
| NasopharyngitisInfections and infestations | 2/19 | 0/9 |
| Age, Continuous(years) | JointStem | Synvisc-One | Total |
|---|---|---|---|
| Mean | 52.3 ± 6.98 | 52.1 ± 9.56 | 52.3 ± 7.72 |
| Sex: Female, Male(Participants) | JointStem | Synvisc-One | Total |
|---|---|---|---|
| Female | 8 | 2 | 10 |
| Male | 11 | 7 | 18 |
| Ethnicity (NIH/OMB)(Participants) | JointStem | Synvisc-One | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 18 | 8 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | JointStem | Synvisc-One | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 16 | 7 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Height(cm) | JointStem | Synvisc-One | Total |
|---|---|---|---|
| Mean | 173.66 ± 9.222 | 169.46 ± 10.073 | 172.31 ± 9.527 |
| Weight(kg) | JointStem | Synvisc-One | Total |
|---|---|---|---|
| Mean | 81.31 ± 14.642 | 71.66 ± 20.569 | 78.2 ± 17.01 |
| BMI(kg/m^2) | JointStem | Synvisc-One | Total |
|---|---|---|---|
| Mean | 26.903 ± 4.1938 | 24.572 ± 4.6408 | 26.154 ± 4.3971 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2016 to primary completion in Mar 2018, 24 months.
Results were first posted in Jul 2021, 3 years 4 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 24 months is above that.
Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nature Cell Co. Ltd.